Chronic GvHD risk assignment algorithms for preemptive therapy
| . | Time measured . | Age group . | Components . | ROC AUC, PPV, NPV . | Validated . | Reference . |
|---|---|---|---|---|---|---|
| cGvHD MS-14 | Days 100, 180, 280, 365 | Adult | Successfully sequenced 6 of the 14 cGvHD naturally occurring peptides. In patients with cGvHD, increased thymosin β-4, eukaryotic translation initiation factor 4γ2, fibrinogen β-chain, and specific fragments of collagen, 1 peptide derived from collagen α-1(I) and another derived from collagen α-2(V), and collagen α-1(III) fragment decreased. | 0.83–0.88 ROC AUC = 0.88 PPV = NA NPV = NA | Yes | 43 |
| ABLE | Day 100 | Pediatric | Polyomic (immune phenotyping, cytokines, metabolome, clinical) | ROC AUC = 0.80 PPV = 0.75 NPV = 0.74 | No | Unpublished |
| Day 100 | Adult | ST2, CXCL9, matrix metalloproteinase 3, and osteopontin | ROC AUC = 0.65–0.69 PPV = 0.22–0.32 NPV = 0.88–0.92 | Yes | 44 |
| . | Time measured . | Age group . | Components . | ROC AUC, PPV, NPV . | Validated . | Reference . |
|---|---|---|---|---|---|---|
| cGvHD MS-14 | Days 100, 180, 280, 365 | Adult | Successfully sequenced 6 of the 14 cGvHD naturally occurring peptides. In patients with cGvHD, increased thymosin β-4, eukaryotic translation initiation factor 4γ2, fibrinogen β-chain, and specific fragments of collagen, 1 peptide derived from collagen α-1(I) and another derived from collagen α-2(V), and collagen α-1(III) fragment decreased. | 0.83–0.88 ROC AUC = 0.88 PPV = NA NPV = NA | Yes | 43 |
| ABLE | Day 100 | Pediatric | Polyomic (immune phenotyping, cytokines, metabolome, clinical) | ROC AUC = 0.80 PPV = 0.75 NPV = 0.74 | No | Unpublished |
| Day 100 | Adult | ST2, CXCL9, matrix metalloproteinase 3, and osteopontin | ROC AUC = 0.65–0.69 PPV = 0.22–0.32 NPV = 0.88–0.92 | Yes | 44 |
AUC, area under the curve; NA, not available; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operator curve.